Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Mount Sinai Tisch Cancer Center"


1 mentions found


CNN —A drug used in people in the early stage of the most common kind of breast cancer – HR+/HER2- breast cancer – significantly reduced the risk of the cancer returning after treatment, according to a new study. HR+/HER2- breast cancer has tested positive for progesterone and estrogen receptors and negative for HER2. Endocrine therapy generally works well, but for patients with HR+ or HER- breast cancer, there’s still a 10% to 40% chance that the cancer will come back, some studies show. The new trial found that when Kisqali is added to endocrine therapy, it reduces the risk of recurrence by 25% across a broad population of patients with early breast cancer. About 90% of patients who have breast cancer are diagnosed in the early stages.
Persons: there’s, Kisqali, , Dennis J, Slamon, Sara Tolaney, ” Tolaney, Anupama Goel, Goel, Dr, Sanjay Gupta, Alberto Montero, ” Montero, Montero Organizations: CNN, US Food and Drug Administration, American Society of Clinical Oncology, Novartis, UCLA, Comprehensive Cancer Center, Oncology, Dana, Farber Cancer Institute, Mount Sinai Tisch Cancer Center, CNN Health, UH Seidman Cancer Center, Case Western Reserve University School of Medicine Locations: Chicago, Ohio,
Total: 1